Urinary liver-type fatty acid-binding protein change in gestational diabetes mellitus.

Wen-jin Fu,Du-Juan Wang,Ren-tang Deng,Zhi-Hong Huang,Mei-lian Chen,You-Ming Jang,Shu Wen,Hong-Ling Yang,Xianzhang Huang

DOI: https://doi.org/10.1016/j.diabres.2015.02.029

IF: 8.18

2015-09-01

Diabetes Research and Clinical Practice

Abstract:

What problem does this paper attempt to address?

Efficacy of Intragastric Balloons for Weight Loss in Overweight and Obese Adults: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Ana Paula Samy Tanaka Kotinda,Diogo Turiani Hourneaux de Moura,Igor Braga Ribeiro,Shailendra Singh,Alberto Machado da Ponte Neto,Igor Mendonça Proença,Marcelo Mochate Flor,Karina Lopes de Souza,Wanderley Marques Bernardo,Eduardo Guimarães Hourneaux de Moura

DOI: https://doi.org/10.1007/s11695-020-04558-5

2020-04-16

Obesity Surgery

Abstract:Intragastric balloons (IGB) are the most widely used endoscopic bariatric and metabolic therapies. We aimed to evaluate the efficacy of IGB in comparison with sham or lifestyle interventions for weight loss in overweight and obese patients. This systematic review and meta-analysis was performed following the PRISMA guidelines. Electronic searches were performed to identify randomized controlled trials, which compared IGB with sham or lifestyle intervention. Thirteen RCTs with 1523 patients were included. The difference in mean %EWL and %TWL at follow-up was 17.98%, and 4.40%, respectively, which was significantly higher in the IGB group. Similarly, the difference in mean AWL and BMIL was 6.12 kg, and 2.13 kg/m2, respectively. IGB therapy is more effective than lifestyle intervention alone for weight loss in overweight and obese adults.

surgery
Effectiveness of Intra-Gastric Balloon as a Bridge to Definitive Surgery in the Super Obese

William Ball,Syed Soulat Raza,John Loy,Manel Riera,Jayaprakash Pattar,Samuel Adjepong,James Rink

DOI: https://doi.org/10.1007/s11695-019-03794-8

Abstract:Background: British National guidelines (NICE) recommend bariatric surgery for patients with a body mass index (BMI) > 40 kg/m2, or BMI > 35 kg/m2 with any comorbidities of the metabolic syndrome. Intra-gastric balloons (IGB) can be used in super obese patients as a first step, before definitive surgery. Aims: Quantify weight loss 6 months after IGB placement, measure progression to definitive surgery and identify complications. Methods: Data collected retrospectively on 50 patients. Forty-six proposed for definitive bariatric surgery, four patients excluded. Analysis performed using SPSS v23.0. Results: Median weight decreased from 165.5 to 155 kg (range 78 to 212, p < 0.01), BMI from 57.4 to 52.15 (range 32.9 to 70.5, p < 0.01), percentage excess weight loss (%EWL) was 12.9% (range - 3.3 to 64.66%, p < 0.01) and BMI reduction was 4.25 kg/m2 (range - 1.3 to 13.9, p < 0.01). Twenty-nine out of 46 patients (63%) progressed to definitive bariatric surgery. Ten out of 46 patients (21.7%) had complications requiring readmission. Seven of these patients required early balloon removal and six failed to progress to definitive surgery. Six patients had a second balloon placement, their actual weight loss was less successful, with some regaining weight. Discussion: IGB is useful to aid weight loss prior to definitive bariatric surgery. Results from first balloon placement are encouraging and comparable with other studies "as reported by Genco et al. (Int J of Obes 30:129-133, 2006)." Readmission due to nausea, vomiting, dehydration and poor compliance may be associated with poor weight loss and failure to progress to definitive surgery. Second balloon placements were less successful. Conclusion: IGB as bridging therapy is a safe and useful adjunct. Sequential IGBs do not seem to provide additional benefit.
Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis

DOI: https://doi.org/10.1007/s11695-022-06437-7

2023-01-13

Obesity Surgery

Abstract:It is estimated that by 2030, 38% of the world population will be overweight, and another 20% will be people with obesity. Intragastric balloons (IGBs) are an option in conjunction with lifestyle modification for the treatment of obesity. We sought to investigate the effects of IGB therapy on hemoglobin A1c (A1c), systolic and diastolic blood pressure (SBP, DBP), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (TGs).

surgery
Annual prognostic factors in chronic heart failure in patients over 80 years old.

A. Cichocka-Radwan,M. Lelonek

DOI: https://doi.org/10.5603/KP.a2016.0132

2016-08-22

Kardiologia Polska

Abstract:BACKGROUND In the elderly the most common cause of hospitalisation and the leading cause of death is heart failure (HF). AIM The purpose was to determine prognostic factors in chronic HF (CHF) in octogenarians and nonagenarians. METHODS The analysis included 197 consecutive patients over 80 years old (mean age 83.63 ± 3.01 years; 46.19% men) hospitalised in 2010-2013 due to CHF. Sixty-two parameters were investigated, such as: age, gender, New York Heart Asso-ciation functional class, body mass index, blood pressure, other comorbidities, the parameters of the 12-lead resting electro-cardiography and the echocardiography, the results of basic laboratory tests, and selected biomarkers, including N-terminal pro-B-type natriuretic peptide, high-sensitive troponin T (hs-TnT), and high-sensitive C-reactive protein. Participants remained in a prospective follow-up for 12 months. We defined the primary endpoint as death due to cardiovascular causes and the composite endpoint, which consisted of: death due to cardiovascular causes and/or hospitalisation for exacerbation of CHF. Follow-up concerning the deaths was performed in 189 patients, composite endpoint in 168 and hospitalisation in 166. The uni- and multivariate logistic regression stepwise analysis was performed for the entire population, according to left ventricular ejection fraction (LVEF < 45% and ≥ 45%) and in the group with glomerular filtration rate (GFR) < 60 mL/min. RESULTS Patients who died constituted 11.1% of the study population (21/189). In multivariate analysis four variables were independently associated with the primary endpoint: GFR (OR = 0.92), hypertension (OR = 0.19), lung diseases (OR = 9.36), and vascular diseases (OR = 6.07). In turn, in the group of patients who reached the composite endpoint (55/168; 32.7%), the only statistically significant independent variable was anaemia (OR = 4.71). In the subpopulation of patients with LVEF < 45% the prognostics for each endpoint were vascular diseases and lung diseases, and they increased the risk from 10- to 24-fold. In the subgroup of patients with LVEF ≥ 45% the independent variable associated with the composite endpoint was haemoglobin (OR = 0.61), in turn for death the prognostics were: white blood cell count, hs-TnT, and vascular diseases (respectively OR = 1.30; OR = 1.04; OR = 3.96). In the population with GFR < 60 mL/min variables with prognostic importance for the composite endpoint were red blood cell parameters: red blood cell distribution width (OR = 1.42) and anaemia (OR = 3.79), while for occurrence of death they were the same as for the entire population - vascular (OR = 5.16) and lung diseases (OR = 4.72). CONCLUSIONS In patients over 80 years old with CHF, comorbidities are of important prognostic value for annual prognosis. The most aggravating factor in studied subgroups was lung disease.
Safety and Efficacy of 12-Month Intra-gastric Balloon-Series of over 1100 Patients

Tom Wiggins,Ojasvi Sharma,Yasmin Sarfaraz,Heather Fry,Julia Baker,Rishi Singhal

DOI: https://doi.org/10.1007/s11695-023-06953-0

Abstract:Background: Intra-gastric balloons (IGB) are a mainstay of endoscopic treatment of overweight and obesity. In recent years, an IGB which can remain in situ for 12 months has been developed. The current study aimed to analyse the safety and efficacy of this 12-month IGB. Methods: Consecutive patients receiving the Orbera 365TM IGB (Apollo Endosurgery, TX, USA) between September 2017 and August 2021 were included in a prospective database. Patients received regular follow-up consultations followed by endoscopic removal at 12 months. Demographic data along with weight loss data were collected. All adverse events were recorded. Results: In total, 1149 patients were included in the study. A majority of the patients were female (87.13%). Median body mass index (BMI) prior to insertion was 36.30 kg/m2 (IQR 32.60-40.00 kg/m2). Median absolute weight loss for all patients was 11.36 kg (IQR 6.70-16.82 kg). There was ongoing sustained weight loss until device removal at week 52. For patients with a weight recording at point of IGB removal, median weight loss was greater (15.88 kg, IQR 10.43-21.72) with percentage total body weight loss of 15.38% (IQR 10.99-21.77) and excess weight loss of 53.99% (IQR 32.44-76.30). Increased patient engagement with post-procedural follow-up was associated with increased weight loss (p<0.001). There were 60 total complications (5.22%). Fifty patients required balloon removal due to intolerance. There were eight cases of balloon rupture. There were only two severe complications (0.17%). Conclusion: The current study has confirmed safety of this IGB at 12 months with adverse events comparable to published literature. Weight loss increased up until the point of removal at 12 months.
[Incidence of hypertension in a cohort of Spanish university graduates: the SUN study].

J. Beunza,M. Martínez-González,M. Serrano-Martínez,Á. Alonso

DOI: https://doi.org/10.1016/S1885-5857(07)60090-5

IF: 7.05

Revista Española de Cardiología

Abstract:
Stability indicating thin-layer chromatographic determination of chlorzoxazone, diclofenac sodium and paracetamol as bulk drug: Application to forced degradation study

M. Kulkarni,Pratibha B. Dange,S. Walode

Abstract:A simple, sensitive and precise thin-layer chromatographic method for determination of chlorzoxazone, diclofenac sodium and paracetamol both as bulk drug and in formulations was developed and validated. The separation was achieved on silica gel 60F-254 thin-layer chromatographic (TLC) plate as the stationary phase and the mobile phase consisted of toluene-ethyl acetate-glacial acetic acid (6.5:3.5:0.02 v/v/v). The solvent system was found to give compact spot for chlorzoxazone (Rf values of 0.23 ± 0.021), diclofenac sodium (Rf values of 0.51 ± 0.035) and paracetamol (Rf values of 0.64 ± 0.028). Densitometric analysis was carried out in the absorbance mode at 274 nm. The linear regression analysis data for the calibration plots showed good linear relationship with respect to peak area in the concentration range 200–800 ng spot-1 of chlorzoxazone (with r = 0.9974), 40–160 ng spot-1 of diclofenac sodium (with r = 0.9914) and 260–1040 ng spot-1 of paracetamol (with r = 0.9965). The method was validated for limit of detection, limit of quantitation, accuracy, precision, robustness and recovery. Chlorzoxazone, diclofenac sodium and paracetamol were subjected to acid and alkali hydrolysis, oxidative, heat treatment and photodegradation. The drug undergoes degradation under acidic and oxidative conditions and upon UV light treatment. The degraded products were well separated from the pure drugs. The result and statistical analysis proves that the developed method is reproducible and selective for the estimation of said drugs. As the method could effectively separate the drugs from its degradation product, it can be employed as stability indicating one.
Outcomes with Intra-gastric Balloon Therapy in BMI < 35 Non-morbid Obesity: 10-Year Follow-Up Study of an RCT

Daniel L Chan,Josil R Cruz,Wilfred L Mui,Simon K H Wong,Enders K W Ng

DOI: https://doi.org/10.1007/s11695-020-04986-3

Abstract:Purpose: Intra-gastric balloon (IGB) therapy is the most established endoscopic treatment of obesity, but there is a paucity of literature on long-term efficacy. This study aims to evaluate the short- and long-term weight loss efficacy of IGB. Materials and methods: Double-blinded RCT with 6-month IGB vs with sham endoscopy, in body mass index (BMI) 27-35 patients. Anthropometric, fasting glucose, and lipid profile measurement as early outcomes (up to 2 years) and 10-year follow-up. Primary outcomes were total body weight loss (kg) and BMI. Secondary outcomes were new-onset diabetes mellitus, other new comorbidities, and willingness for further intervention. Results: Initial RCT recruited 99 patients (50 IGB vs 49 sibutramine group). Forty-nine patients (26 IGB vs 23 control group) participated in a 10-year review (follow-up rate of 51.6%). Total body weight loss at 6 (9.75 vs 7.48 kg, p = 0.03), 12 (6.52 vs 4.42 kg, p = 0.05), 18 (5.42 vs 3.57, p = 0.32), and 24 months (4.07 vs 2.93 kg, p = 0.56) favored the IGB group. Total weight loss (TWL) at 10 years (0.03 vs - 2.32 kg, p = 0.05) and %TWL (- 0.16 ± 12.8% vs - 2.84 ± 5.6%, p = 0.39) were not significantly different between groups. Follow-up BMI (30.97 ± 1.6 vs 30.38 ± 1.8 kg/m2, p = 1.00) was similar. At 10 years, new-onset diabetes mellitus, sleep apnoea, metabolic syndrome, and arthralgia were not significant (p > 0.05). Twenty-three (81%) IGB group vs 13 (56%) control expressed a willingness for further intervention (p < 0.01). Conclusion: IGB delivers weight loss to 2 years and is superior to control. However, new comorbidity development is not significantly different at 10 years. Patient that received IGB therapy were subsequently more willing for further bariatric metabolic intervention.
Effectiveness and Safety of the Allurion Swallowable Intragastric Balloon for Short-term Weight Loss: A Systematic Review and Meta-analysis

Adriana Fernandes Silva,Alexandre Moraes Bestetti,Angelo So Taa Kum,Beanie Conceição Medeiros Nunes,Matheus de Oliveira Veras,Wanderley Marques Bernardo,Eduardo Guimarães Hourneaux de Moura

DOI: https://doi.org/10.1007/s11695-024-07453-5

2024-08-26

Obesity Surgery

Abstract:Obesity poses a severe health problem worldwide, with an estimated impact on 17.5% of the adult population by 2035. Among the endoscopic applications for treating this comorbidity, intragastric balloons are the most widely used. The new liquid-filled swallowable balloon meets the requirements of major guidelines and allows significant weight loss with few adverse events. This systematic review and meta-analysis aims to demonstrate the efficacy and safety profile of this new device for weight loss.

surgery
Changes in Body Adiposity, Dietary Intake, Physical Activity and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy for 6 Months

Marcella Rodrigues Guedes,Ricardo José Fittipaldi-Fernandez,Cristina Fajardo Diestel,Márcia Regina Simas Torres Klein

DOI: https://doi.org/10.1007/s11695-018-3609-x

2018-12-07

Obesity Surgery

Abstract:BackgroundObesity is an important risk factor for several chronic diseases and also is associated with worse quality of life. Intragastric balloon (IGB) is an effective method for weight loss. Although changes in lifestyle are critical to weight loss during and after IGB therapy, only a few studies evaluated dietary intake and none evaluated changes in physical activity with a validated questionnaire during the treatment. The aim of this study was to evaluate changes in total and central body adiposity, dietary intake, physical activity, and quality of life of patients with obesity submitted to IGB treatment for 6 months.MethodsProspective observational study involving 42 patients with obesity using IGB for 6 months. The patients were evaluated, on the day of insertion and withdrawal or adjustment of IGB for total and central body adiposity (anthropometry and bioelectrical impedance), dietary intake, physical activity (Baecke questionnaire), and quality of life (SF-36 questionnaire).ResultsThere was a significant decrease in total and central body adiposity. The mean % total weight loss and % excess weight loss were 15.88 ± 1.42 and 56.04 ± 4.90, respectively and waist circumference decreased 13.33 ± 1.39 cm. There was a reduction in energy intake, an increase in physical activity, and an improvement of quality of life during IGB treatment.ConclusionThe present study suggests that IGB treatment during 6 months in individuals with obesity is effective for decreasing total and central body adiposity being associated with reduction in energy intake, increase in physical activity, and improvement in quality of life.

surgery
Safety and Effectiveness of Two Different Fluid-Filled Intragastric Balloons: A Single Center Experience

Almahmeed, Husain,Hamshari, Fatima,Almousawi, Ahmed,Qasem, Wafaa

DOI: https://doi.org/10.1007/s11695-024-07524-7

2024-10-03

Obesity Surgery

Abstract:The aim of the study is to compare weight loss and safety outcomes of two different commonly available fluid-filled intragastric balloons (IGBs) used for weight loss.

surgery
Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial

A Courcoulas,B K Abu Dayyeh,L Eaton,J Robinson,G Woodman,M Fusco,V Shayani,H Billy,D Pambianco,C Gostout

DOI: https://doi.org/10.1038/ijo.2016.229

2016-12-23

International Journal of Obesity

Abstract:Background/objectives:This trial evaluated the safety and effectiveness of the Orbera Intragastric Balloon as an adjunct to lifestyle intervention.Subjects/methods:In this multicenter, randomized, open-label clinical trial, 255 adults with a body mass index of 30–40 kg m−2 were treated and outcomes were assessed up to 12 months. Participants were randomized to endoscopic placement of an intragastric balloon plus lifestyle or lifestyle intervention alone. Balloons were removed at 6 months and lifestyle intervention continued for both groups through 12 months. At 9 months, coprimary end points were two measures of weight loss.Results:At 6 months, weight loss was −3.3% of total body weight (−3.2 kg) in the lifestyle arm vs −10.2% (−9.9 kg) in the balloon plus lifestyle arm (P<0.001); at 9 months (3 months postballoon removal), weight loss was −3.4% (−3.2 kg) vs −9.1% (−8.8 kg, P⩽0.001); and at 12 months, −3.1% (−2.9 kg) vs −7.6% (−7.4 kg, P⩽0.001). For the primary end points, at 9 months, mean percent loss of weight in excess of ideal body weight (s.d.) at 9 months was 26.5% (20.7) (P=0.32) and 9.7% (15.1) in the balloon and control groups, respectively. Also, 45.6% (36.7, 54.8) of the subjects randomized to the balloon achieved at least 15% loss of weight in excess of ideal body weight greater than the control group (P<0.001). The majority of balloon subjects experienced adverse events; 86.9% nausea, 75.6% vomiting, 57.5% abdominal pain and 18.8% had their device removed before 6 months because of an adverse event or subject request. Five subjects (3.1%) in the balloon group had a gastric abnormality at the time of device removal, and no ulcers were found.Conclusions and relevance:Intragastric balloon achieved greater short-term weight loss at 3 and 6 months postballoon removal than lifestyle intervention alone. Adverse gastrointestinal events were common.

endocrinology & metabolism,nutrition & dietetics
Evaluating the Safety of the Intragastric Balloon: Spanish Multicenter Experience in 20,680 Cases and with 12 Different Balloon Models

Eduard Espinet-Coll,Andrés J. Del Pozo-García,Román Turró-Arau,Javier Nebreda-Durán,Xavier Cortés-Rizo,Andrés Serrano-Jiménez,Miguel Ángel Escartí-Usó,María Muñoz-Tornero,David Carral-Martínez,Jaime Bernabéu-López,Cristian Sierra-Bernal,David Martínez-Ares,Jesús Espinel-Díez,Carlos Marra-López Valenciano,Javier Sola-Vera,Laura Sanchís-Artero,José Luís Domínguez-Jiménez,Ramiro Carreño-Macián,José Francisco Juanmartiñena-Fernández,Arnulfo Fernández-Zulueta,Claudia Consiglieri-Alvarado,Manoel Galvao-Neto,Collaborators for the "Spanish Bariatric Endoscopy Group (GETTEMO) of the Spanish Society of Digestive Endoscopy (SEED)"

DOI: https://doi.org/10.1007/s11695-024-07342-x

2024-07-19

Obesity Surgery

Abstract:Intragastric balloon (IGB) is a minimally invasive and reversible option for obesity treatment. There is a worldwide growing number of different IGB models. The efficacy and safety profile for each model must be demonstrated. We aim to evaluate IGB safety profile according to the experience of the Spanish Bariatric Endoscopy Group (GETTEMO).

surgery
Renal angiography under the influence of vasopressin and bradykinin.

B. Carlsson,U. Erikson

DOI: https://doi.org/10.2214/AJR.109.1.161

1970-05-01

Abstract:
Intragastric Balloon as a Noninvasive Method for Obesity Treatment: A Single-Center Retrospective Study

Levent Eminoğlu

DOI: https://doi.org/10.62713/aic.3376

2024-04-20

Annali italiani di chirurgia

Abstract:Background: The incidence of obesity is increasing globally, with approximately 1 in 3 adults either overweight or obese. Surgery provides the most effective treatment for advanced obesity; however, endoscopic treatment, including intragastric balloon therapy, is commonly used in patients who do not meet the indications for surgery. Our study aimed to evaluate short- and mid-term weight changes of patients who had intragastric balloon therapy. Material and Methods: In this single-center retrospective study, we enrolled 320 patients with body mass index (BMI) values between 30 and 40 kg/m2 and without comorbidities, who underwent intragastric balloon treatment. 284 patients successfully underwent the operation. All patients were followed-up at 6 months after treatment, balloons were removed, and BMIs were recorded. Further follow-up was performed 6 months after balloon removal, and patients' BMI and demographic data were recorded again. Results: Overall, 320 patients were enrolled in this study. In this cohort, 82 returned to their preprocedural weight at 1 year postprocedure, whereas 260 had BMI lower than the preprocedural values, but higher than the values at 6 months postprocedure. None of the patients had lower BMI compared to their 6-month postprocedural values. Conclusions: Balloon therapy typically helps patients lose 10% of body weight. Intragastric balloons are effective when used as weight loss tools, but are ineffective at maintaining weight loss. An intragastric device placed for 6 months may also be expected to help the patients develop better eating habits; however, we did not encounter this lifestyle change in our series.

surgery
Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor.

S. Padi,N. K. Jain,Sukhjeet Singh,S. Kulkarni

DOI: https://doi.org/10.1016/J.EJPHAR.2004.03.013

IF: 5.195

2004-04-26

European Journal of Pharmacology

Abstract:
Influence of the Brain-Derived Neurotrophic Factor Gene Polymorphism on Weight Loss Following Intragastric Balloon Intervention: A Cross-Sectional Study

Ahmad Al-Serri,Hessa Al-Janahi,Mohammad Jamal,Dana AlTarrah,Ali Ziyab,Suzanne Al-Bustan

DOI: https://doi.org/10.2147/dmso.s481547

2024-11-27

Diabetes Metabolic Syndrome and Obesity Targets and Therapy

Abstract:Ahmad Al-Serri, 1 Hessa A Al-Janahi, 1 Mohammad H Jamal, 2 Dana AlTarrah, 3 Ali H Ziyab, 4 Suzanne A Al-Bustan 5 1 Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait; 2 Department of Surgery, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait; 3 Department of Social and Behavioral Science, Faculty of Public Health, Kuwait University, Kuwait City, Kuwait; 4 Department of Community Medicine and Behavioral Sciences, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait; 5 Department of Biological Sciences, Faculty of Science, Kuwait University, Kuwait City, Kuwait Correspondence: Ahmad Al-Serri, Human Genetics Unit, Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait, Tel +965 2463 6231, Fax +965 25338905, Email Background and Aim: There is noticeable heterogeneity in weight loss outcomes following intragastric balloon (IGB) treatment, with average weight loss ranging between 11% to 15% of total body weight. Genetic variations associated with obesity have been found to influence weight loss response, however such variations are limited. Therefore, the aim of this study is to investigate the impact of the obesity associated brain-derived neurotrophic factor (BDNF) gene polymorphism rs11030104 with weight loss outcomes following IGB treatment. Methods: In this cross-sectional study, BDNF rs11030104 was analysed in 106 individuals who underwent intragastric balloon treatment. Weight loss metrics were evaluated at the three-month follow-up: percentage of total weight loss (%TWL), percentage of excess weight loss (%EWL), and percentage of body mass index loss (%EBMIL). The effects of additive and dominant genetic models were evaluated. Both linear and logistic regression were applied to assess associations between rs11030104 genotypes and weight loss metrics. Results: A total of 71 participants completed the 3-month follow-up assessment (loss to follow-up: 33%). This study found a significant association between the BDNF rs11030104 polymorphism and weight loss. A-allele carriers showed a better response to IGB treatment. Individuals carrying the AA genotype were found to have a greater %TWL than those carrying the GG genotype at 3 months post-IGB treatment (11.05% vs 5.09%, p=0.003). Conclusion: Our results suggest that BDNF rs11030104 influences the response to weight loss after IGB treatment and therefore could be added to the growing list of genetic variants that predict greater weight loss response. Keywords: BDNF, polymorphism, obesity, intragastric balloon, BMI, weight loss The rate of obesity is increasing at an alarming pace, with certain populations exceeding 50%. According to the world health organization, obesity has doubled in adults and quadrupled in adolescents since 1990. 1 This significant increase has resulted in an urgency to develop treatments for the management of obesity. 2 Among these treatments, medical and surgical devices have become widely available through the use of a variety of techniques and procedures. 3 The intragastric balloon (IGB) is an FDA-approved minimally invasive intervention for weight loss that has been widely used. 4 The implantation of the IGB in the stomach for a specified period of time reduces the stomach capacity. This mechanistic approach provides a sensation of satiety leading to the consumption of smaller meals and, in turn, results in weight loss. 5,6 A meta-analysis of 40,000 subjects showed that IGB treatment resulted in weight loss between 11% and 15% of total body weight at the 6-month follow-up. 7 In addition, several randomized clinical trials have shown that IGB is an effective treatment option for the management of obesity. In particular, compared with conventional treatments, IGB has been shown to cause significant weight loss in combination with lifestyle modifications. 8,9 Although weight loss is observed among patients undergoing IGB, interindividual variation in weight loss is evident. For instance, a meta-analysis reported that weight loss among IGB patients varied widely, where treatment resulted in no weight loss or extreme weight loss in some patients, reaching up to 87.5 kilograms (kg). 7,10 Heterogeneity in weight loss is broadly attributed to well-established lifestyle factors, such as the level of physical activity and caloric intake. 11 In addition to lifestyle factors, genetics also contributes to weight loss outcomes after treatment. 12 Genetic variations associated with obesity have been shown to influence weight loss among individuals undergoi -Abstract Truncated-

endocrinology & metabolism
Intragastric Balloons: Practical Considerations

D T H de Moura,Sergio A Sánchez-Luna,Adriana Fernandes Silva,Alexandre Moraes Bestetti

DOI: https://doi.org/10.1016/j.giec.2024.04.013

Abstract:Obesity is escalating, projected to affect 17.5% of adults globally and afflict 400 million children by 2035. Managing this intricate and chronic condition demands personalized, multidisciplinary approaches. While dietary changes, lifestyle modifications, and medications yield short-term results, long-term outcomes are often poor, with bariatric surgery standing out as the most effective option. However, only a small fraction undergoes surgery due to various barriers. Intragastric balloon (IGB) emerges as a minimally invasive alternative, approved by major regulatory bodies. This review adresses the pivotal role of IGB in obesity management, delving into its history and technological evolution.
Small Bowel Obstruction Following Dislodgement of an Intragastric Balloon: A Case Report

Laura Brizuela,Hani Samarah,Nicole Cardona

DOI: https://doi.org/10.7759/cureus.67738

2024-08-25

Cureus

Abstract:Obesity remains a significant health burden worldwide, requiring diverse and effective treatment strategies. The intragastric balloon (IGB), developed in the 1980s, offers a non-surgical option for weight management. Despite a decrease in usage, the IGB procedure continues to be an option for patients both domestically and abroad. In this article, we present the case involving a 30-year-old female who presented with severe abdominal complications 18 months after IGB placement in the Dominican Republic, well beyond the recommended six-month period for removal. This case highlights the critical risks associated with delayed IGB removal, including balloon rupture, migration, and symptoms indicative of gastric outlet obstruction. The literature supports increased complication rates with prolonged balloon retention, including risks such as gastric perforation, ulceration, and small bowel obstruction, emphasizing the importance of adhering to removal schedules. Furthermore, the case stresses the need for psychosocial evaluations before weight loss procedures and the necessity of alternative methods like laparoscopic removal when endoscopic extraction is unsuccessful. As obesity management evolves with new treatments like glucagon-like peptide-1 (GLP-1) analogs, ongoing research to understand their interaction with IGBs is crucial. This case underlines the importance of rigorous follow-up care, educating patients about procedural timelines, and conducting comprehensive evaluations to ensure the safety and effectiveness of IGB therapy.
Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon-a Case-Matched Study

Dilhana Badurdeen,Anna Carolina Hoff,Sergio Barrichello,Abdellah Hedjoudje,Mohamad I Itani,Jad Farha,Shahem Abbarh,Atif Adam,Vikesh K Singh,Saowanee Ngamruengphong,Andreas Oberbach,Mouen A Khashab,Manoel Galvao Neto,Vivek Kumbhari

DOI: https://doi.org/10.1007/s11695-020-05117-8

Abstract:Purpose: Weight regain after balloon retrieval is a concern with all intra-gastric balloons (IGBs). The aim of this study was to evaluate the efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, to prevent weight regain following IGB retrieval. Materials and methods: This was a case-matched study of patients undergoing Spatz3 adjustable IGB (Spatz FGIA, Inc. NY, USA) at three outpatient clinics in Brazil between November 2015 and January 2019. Seventy-seven patients that opted to take liraglutide following IGB retrieval (IGB-L) were matched 1:1 to 198 patients that declined the medication-IGB-Alone (IGB-A). Propensity score adjustment was performed at the time of balloon retrieval on factors known to influence the choice of liraglutide. Weight and percent body fat (%BF) was measured at baseline and 9 months after IGB retrieval. % BF is defined as the total mass of fat divided by total body mass, multiplied by 100. The primary outcome was weight regain, and the secondary outcome was change in %BF 9 months after IGB retrieval. Results: Propensity score matching yielded 53 matched pairs. Weight regain to the starting point was not observed in either group. There was significantly less weight regain in IGB-L compared to IGB-A, - 1.15 ± 0.94 kg versus - 0.66 ± 0.99 kg (p = 0.010) 9 months after balloon retrieval. Additionally, %BF decline in IGB-L was superior to IGB-A - 10.83 ± 1.50 versus - 7.94 ± 2.02 (p < 0.01). There was no difference in weight regain or decline in %BF based on liraglutide dose. Conclusion: Liraglutide has an additive benefit with respect to efficacy and a reduction in body fat when commenced after IGB retrieval. Future randomized control studies will be needed to determine the optimal dose and duration of liraglutide to achieve superior outcomes.

Urinary liver-type fatty acid-binding protein change in gestational diabetes mellitus.

Efficacy of Intragastric Balloons for Weight Loss in Overweight and Obese Adults: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Effectiveness of Intra-Gastric Balloon as a Bridge to Definitive Surgery in the Super Obese

Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis

Annual prognostic factors in chronic heart failure in patients over 80 years old.

Safety and Efficacy of 12-Month Intra-gastric Balloon-Series of over 1100 Patients

[Incidence of hypertension in a cohort of Spanish university graduates: the SUN study].

Stability indicating thin-layer chromatographic determination of chlorzoxazone, diclofenac sodium and paracetamol as bulk drug: Application to forced degradation study

Outcomes with Intra-gastric Balloon Therapy in BMI < 35 Non-morbid Obesity: 10-Year Follow-Up Study of an RCT

Effectiveness and Safety of the Allurion Swallowable Intragastric Balloon for Short-term Weight Loss: A Systematic Review and Meta-analysis

Changes in Body Adiposity, Dietary Intake, Physical Activity and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy for 6 Months

Safety and Effectiveness of Two Different Fluid-Filled Intragastric Balloons: A Single Center Experience

Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial

Evaluating the Safety of the Intragastric Balloon: Spanish Multicenter Experience in 20,680 Cases and with 12 Different Balloon Models

Renal angiography under the influence of vasopressin and bradykinin.

Intragastric Balloon as a Noninvasive Method for Obesity Treatment: A Single-Center Retrospective Study

Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor.

Influence of the Brain-Derived Neurotrophic Factor Gene Polymorphism on Weight Loss Following Intragastric Balloon Intervention: A Cross-Sectional Study

Intragastric Balloons: Practical Considerations

Small Bowel Obstruction Following Dislodgement of an Intragastric Balloon: A Case Report

Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon-a Case-Matched Study